user Sign In

QYResearch Account

Manage your Account and Access Personalized Content.

Sign in

Create Account with us

Manage your Account and Access Personalized Content.

Sign Up
       
  
×

Global Hirudin Market Report, History and Forecast 2013-2025, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published Date: 2018-09-12   |   Pages: 136   |   Tables: 168   | Report Id: 333043   | Hits: 115 |   Chemical & Material



Summary

This report studies the Hirudin market size (value and volume) by players, regions, product types and end industries, history data 2013-2017 and forecast data 2018-2025; This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.

This report studies the Hirudin market. Hirudin is a naturally occurring peptide in the salivary glands of medicinal leeches (such as Hirudo medicinalis) that has a blood anticoagulant property. Hirudin is the most potent natural inhibitor of thrombin.

Hirudin (hirudin) is a Leech (Leech) and salivary glands have been extracted from a variety of active ingredients in the activity of the most significant and most studied ingredients, which is 65-66 amino acids from the small molecules of protein (peptide) . Hirudin have strong inhibitory effect on thrombin is the strongest so far found in the natural specific inhibitor of thrombin. Animal experiments and clinical studies have shown that hirudin can be effective anticoagulant, antithrombotic, and prevent thrombin-catalyzed activation of coagulation factors and platelet reactions and blood stasis phenomenon further. In addition, it also inhibited thrombin-induced fibroblast proliferation, and thrombin stimulation of endothelial cells. Compared with heparin, which not only use less, do not cause bleeding, is not dependent on endogenous cofactor; and heparin have caused the risk of bleeding, disseminated intravascular coagulation in the pathogenesis of antithrombin III are reduced This will limit the efficacy of heparin, using leeches will have good results.

Hirudin can be effective anticoagulant, antithrombotic, and prevent thrombin-catalyzed activation of coagulation factors and platelet reactions and blood stasis phenomenon further. In addition, it also inhibited thrombin-induced fibroblast proliferation, and thrombin stimulation of endothelial cells. Compared with heparin, which not only use less, do not cause bleeding, is not dependent on endogenous cofactor; and heparin have caused the risk of bleeding, disseminated intravascular coagulation in the pathogenesis of antithrombin III are reduced This will limit the efficacy of heparin, using leeches will have good results.

According to the statistical data, Demand cannot be satisfied with supply. Currently, Hirudin market has a certain potential in USA, Europe and Asia Market. These areas demand are rapidly growth.

In recent years in China as the main ingredient to hirudin, there are many kinds of proprietary Chinese medicines, such as cerebral blood oral liquid, tablets thrombosis, blood capsule, with its annual output value of tens of millions. New drugs with leeches are constantly studied and introduced. Genetic engineering of recombinant leech-like peptide drugs to replace or hirudin as anticoagulant drug additives stasis, which can be achieved in the near future. As the injection for the treatment of cardiovascular diseases and cancer drugs, the need for further clinical research. Needless to say, recombinant hirudin-like peptide drug development will bring huge social and economic benefits.

The global Hirudin market was 3450 million US$ in 2017 and is expected to 4180 million US$ by the end of 2025, growing at a CAGR of 2.4% between 2018 and 2025.

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Hirudin in these regions, from 2013 to 2025, covering

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia and Turkey etc.)

Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)

South America (Brazil etc.)

Middle East and Africa (Egypt and GCC Countries)

The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in this market include

The Medicines Company

Keyken

Minapharm

Abbott

SALUBRIS

Pfizer, Inc

Teva Pharmaceutical Industries Ltd

DUOPUTAI

Pentapharm

By the product type, the market is primarily split into

Natural Hirudin

Recombinant Hirudin

By the end users/application, this report covers the following segments

Thrombosis Disease

Tumor Disease

Others

We can also provide the customized separate regional or country-level reports, for the following regions:

North America

United States

Canada

Mexico

Asia-Pacific

China

India

Japan

South Korea

Australia

Indonesia

Singapore

Malaysia

Philippines

Thailand

Vietnam

Rest of Asia-Pacific

Europe

Germany

France

UK

Italy

Spain

Russia

Rest of Europe

Central & South America

Brazil

Rest of Central & South America

Middle East & Africa

GCC Countries

Turkey

Egypt

South Africa

Rest of Middle East & Africa

The study objectives of this report are:

To study and analyze the global Hirudin market size (value & volume) by company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025.

To understand the structure of Hirudin market by identifying its various subsegments.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

Focuses on the key global Hirudin manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the Hirudin with respect to individual growth trends, future prospects, and their contribution to the total market.

To project the value and volume of Hirudin submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Hirudin are as follows:

History Year: 2013-2017

Base Year: 2017

Estimated Year: 2018

Forecast Year 2018 to 2025

This report includes the estimation of market size for value (million USD) and volume (MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Hirudin market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Key Stakeholders

Raw material suppliers

Distributors/traders/wholesalers/suppliers

Regulatory bodies, including government agencies and NGO

Commercial research & development (R&D) institutions

Importers and exporters

Government organizations, research organizations, and consulting firms

Trade associations and industry bodies

End-use industries

Available Customizations

With the given market data, QYResearch offers customizations according to the company's specific needs. The following customization options are available for the report:

Further breakdown of Hirudin market on basis of the key contributing countries.

Detailed analysis and profiling of additional market players.

Licenses Type

Only one user can access the report
Multiple users can access the report

Why QYR

 Fastest report delivery service
 More than 10 years of vast experience
 Operational for 24 * 7 & 365 days
 In-depth and comprehensive analysis
 Excellent after sales support
 Owns large database

Need Help ?

QYR Clients

More Clients...